SMAD2 and coronary artery disorder: De novo protein-truncating, splicing, and deleterious missense variants in SMAD2 were identified in a cohort of CHD patients with a variety of defects including complex CHD with or without laterality defects and other congenital anomalies and late-onset vascular phenotype [110].